A monoclonal antibody against the Wnt signaling inhibitor dickkopf-1 inhibits osteosarcoma metastasis in a preclinical model

Seth D. Goldstein, Matteo Trucco, Wendy Bautista Guzman, Masanori Hayashi, David M. Loeb

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The outcome of patients with metastatic osteosarcoma has not improved since the introduction of chemotherapy in the 1970s. Development of therapies targeting the metastatic cascade is a tremendous unmet medical need. The Wnt signaling pathway has been the focus of intense investigation in osteosarcoma because of its role in normal bone development. Although the role of Wnt signaling in the pathogenesis of osteosarcoma is controversial, there are several reports of dickkopf-1 (DKK-1), a Wnt signaling antagonist, possibly playing a pro-tumorigenic role. In this work we investigated the effect of anti-DKK-1 antibodies on the growth and metastasis of patient-derived osteosarcoma xenografts. We were able to detect human DKK-1 in the blood of tumor-bearing mice and found a correlation between DKK-1 level and tumor proliferation. Treatment with the anti-DKK-1 antibody, BHQ880, slowed the growth of orthotopically implanted patient-derived osteosarcoma xenografts and inhibited metastasis. This effect was correlated with increased nuclear beta-catenin staining and increased expression of the bone differentiation marker osteopontin. These findings suggest that Wnt signaling is anti-tumorigenic in osteosarcoma, and support the targeting of DKK-1 as an anti-metastatic strategy for patients with osteosarcoma.

Original languageEnglish (US)
Pages (from-to)21114-21123
Number of pages10
JournalOncotarget
Volume7
Issue number16
DOIs
StatePublished - Apr 19 2016
Externally publishedYes

Fingerprint

Osteosarcoma
Monoclonal Antibodies
Neoplasm Metastasis
Heterografts
Wnt Signaling Pathway
Osteopontin
Antibodies
Bone Development
Differentiation Antigens
beta Catenin
Growth
Neoplasms
Staining and Labeling
Bone and Bones
Drug Therapy
Therapeutics

Keywords

  • DKK-1
  • Metastasis
  • Mouse model
  • Sarcoma
  • Wnt signaling

ASJC Scopus subject areas

  • Oncology

Cite this

A monoclonal antibody against the Wnt signaling inhibitor dickkopf-1 inhibits osteosarcoma metastasis in a preclinical model. / Goldstein, Seth D.; Trucco, Matteo; Guzman, Wendy Bautista; Hayashi, Masanori; Loeb, David M.

In: Oncotarget, Vol. 7, No. 16, 19.04.2016, p. 21114-21123.

Research output: Contribution to journalArticle

Goldstein, Seth D. ; Trucco, Matteo ; Guzman, Wendy Bautista ; Hayashi, Masanori ; Loeb, David M. / A monoclonal antibody against the Wnt signaling inhibitor dickkopf-1 inhibits osteosarcoma metastasis in a preclinical model. In: Oncotarget. 2016 ; Vol. 7, No. 16. pp. 21114-21123.
@article{54e0fd175e5e4220854692324f515815,
title = "A monoclonal antibody against the Wnt signaling inhibitor dickkopf-1 inhibits osteosarcoma metastasis in a preclinical model",
abstract = "The outcome of patients with metastatic osteosarcoma has not improved since the introduction of chemotherapy in the 1970s. Development of therapies targeting the metastatic cascade is a tremendous unmet medical need. The Wnt signaling pathway has been the focus of intense investigation in osteosarcoma because of its role in normal bone development. Although the role of Wnt signaling in the pathogenesis of osteosarcoma is controversial, there are several reports of dickkopf-1 (DKK-1), a Wnt signaling antagonist, possibly playing a pro-tumorigenic role. In this work we investigated the effect of anti-DKK-1 antibodies on the growth and metastasis of patient-derived osteosarcoma xenografts. We were able to detect human DKK-1 in the blood of tumor-bearing mice and found a correlation between DKK-1 level and tumor proliferation. Treatment with the anti-DKK-1 antibody, BHQ880, slowed the growth of orthotopically implanted patient-derived osteosarcoma xenografts and inhibited metastasis. This effect was correlated with increased nuclear beta-catenin staining and increased expression of the bone differentiation marker osteopontin. These findings suggest that Wnt signaling is anti-tumorigenic in osteosarcoma, and support the targeting of DKK-1 as an anti-metastatic strategy for patients with osteosarcoma.",
keywords = "DKK-1, Metastasis, Mouse model, Sarcoma, Wnt signaling",
author = "Goldstein, {Seth D.} and Matteo Trucco and Guzman, {Wendy Bautista} and Masanori Hayashi and Loeb, {David M.}",
year = "2016",
month = "4",
day = "19",
doi = "10.18632/oncotarget.8522",
language = "English (US)",
volume = "7",
pages = "21114--21123",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "16",

}

TY - JOUR

T1 - A monoclonal antibody against the Wnt signaling inhibitor dickkopf-1 inhibits osteosarcoma metastasis in a preclinical model

AU - Goldstein, Seth D.

AU - Trucco, Matteo

AU - Guzman, Wendy Bautista

AU - Hayashi, Masanori

AU - Loeb, David M.

PY - 2016/4/19

Y1 - 2016/4/19

N2 - The outcome of patients with metastatic osteosarcoma has not improved since the introduction of chemotherapy in the 1970s. Development of therapies targeting the metastatic cascade is a tremendous unmet medical need. The Wnt signaling pathway has been the focus of intense investigation in osteosarcoma because of its role in normal bone development. Although the role of Wnt signaling in the pathogenesis of osteosarcoma is controversial, there are several reports of dickkopf-1 (DKK-1), a Wnt signaling antagonist, possibly playing a pro-tumorigenic role. In this work we investigated the effect of anti-DKK-1 antibodies on the growth and metastasis of patient-derived osteosarcoma xenografts. We were able to detect human DKK-1 in the blood of tumor-bearing mice and found a correlation between DKK-1 level and tumor proliferation. Treatment with the anti-DKK-1 antibody, BHQ880, slowed the growth of orthotopically implanted patient-derived osteosarcoma xenografts and inhibited metastasis. This effect was correlated with increased nuclear beta-catenin staining and increased expression of the bone differentiation marker osteopontin. These findings suggest that Wnt signaling is anti-tumorigenic in osteosarcoma, and support the targeting of DKK-1 as an anti-metastatic strategy for patients with osteosarcoma.

AB - The outcome of patients with metastatic osteosarcoma has not improved since the introduction of chemotherapy in the 1970s. Development of therapies targeting the metastatic cascade is a tremendous unmet medical need. The Wnt signaling pathway has been the focus of intense investigation in osteosarcoma because of its role in normal bone development. Although the role of Wnt signaling in the pathogenesis of osteosarcoma is controversial, there are several reports of dickkopf-1 (DKK-1), a Wnt signaling antagonist, possibly playing a pro-tumorigenic role. In this work we investigated the effect of anti-DKK-1 antibodies on the growth and metastasis of patient-derived osteosarcoma xenografts. We were able to detect human DKK-1 in the blood of tumor-bearing mice and found a correlation between DKK-1 level and tumor proliferation. Treatment with the anti-DKK-1 antibody, BHQ880, slowed the growth of orthotopically implanted patient-derived osteosarcoma xenografts and inhibited metastasis. This effect was correlated with increased nuclear beta-catenin staining and increased expression of the bone differentiation marker osteopontin. These findings suggest that Wnt signaling is anti-tumorigenic in osteosarcoma, and support the targeting of DKK-1 as an anti-metastatic strategy for patients with osteosarcoma.

KW - DKK-1

KW - Metastasis

KW - Mouse model

KW - Sarcoma

KW - Wnt signaling

UR - http://www.scopus.com/inward/record.url?scp=84965078942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965078942&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.8522

DO - 10.18632/oncotarget.8522

M3 - Article

VL - 7

SP - 21114

EP - 21123

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 16

ER -